{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:57:58Z","timestamp":1790827078282,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.vaccine.2010.01.015","type":"journal-article","created":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T09:38:12Z","timestamp":1263980292000},"page":"4002-4012","source":"Crossref","is-referenced-by-count":38,"title":["Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis"],"prefix":"10.1016","volume":"28","author":[{"given":"Rajeev","family":"Nagill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.01.015_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2010.01.015_bib2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2010.01.015_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/00034983.1995.11813017","article-title":"Vaccines against leishmaniasis","volume":"89","author":"Modabber","year":"1995","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2010.01.015_bib4","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2010.01.015_bib5","first-page":"1","article-title":"Protection against Leishmania major infection in genetically susceptible BALB\/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-)","volume":"85","author":"Xu","year":"1995","journal-title":"Immunology"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2010.01.015_bib6","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1016\/j.vaccine.2006.04.062","article-title":"Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB\/c mice","volume":"24","author":"Jaafari","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2010.01.015_bib7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/IAI.00611-07","article-title":"gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB\/c mice infected with Leishmania donovani","volume":"76","author":"Bhowmick","year":"2008","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2010.01.015_bib8","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/IAI.61.8.3351-3359.1993","article-title":"Recombinant vaccinia viruses expressing GP46\/M-2 protect against Leishmania infection","volume":"61","author":"McMahon-Pratt","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.01.015_bib9","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/IAI.56.12.3272-3279.1988","article-title":"Membrane glycoprotein M-2 protects against Leishmania amazonensis infection","volume":"56","author":"Champsi","year":"1988","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2010.01.015_bib10","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Ferraz-Coelho","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.01.015_bib11","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/IAI.72.8.4521-4527.2004","article-title":"Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK","volume":"72","author":"Pinto","year":"2004","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2010.01.015_bib12","first-page":"547","article-title":"Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML)","volume":"27","author":"Palatnik de Sousa","year":"1994","journal-title":"Braz J Med Biol Res"},{"issue":"32","key":"10.1016\/j.vaccine.2010.01.015_bib13","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1016\/S0264-410X(03)00527-9","article-title":"Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine","volume":"21","author":"Santos","year":"2003","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2010.01.015_bib14","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/IAI.63.11.4261-4267.1995","article-title":"Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response","volume":"63","author":"Handman","year":"1995","journal-title":"Infect Immun"},{"issue":"20","key":"10.1016\/j.vaccine.2010.01.015_bib15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0264-410X(98)00075-9","article-title":"Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection","volume":"16","author":"Sjolander","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.015_bib16","series-title":"Proceedings of the Third World Congress on Leishmaniosis","first-page":"178","article-title":"Immunization with H1 and HASPB1 Leishmania proteins protect dogs against experimental canine leishmaniasis","author":"Moreno","year":"2005"},{"key":"10.1016\/j.vaccine.2010.01.015_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0264-410X(00)00207-3","article-title":"Immunization with recombinant LD1 antigens protects against experimental leishmaniasis","volume":"19","author":"Dole","year":"2000","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2010.01.015_bib18","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.vaccine.2005.11.058","article-title":"Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis","volume":"24","author":"Tewary","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.015_bib19","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.4049\/jimmunol.150.6.2322","article-title":"Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis","volume":"150","author":"Rachamim","year":"1993","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.01.015_bib20","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1128\/IAI.73.9.5842-5852.2005","article-title":"Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL\/6 mice but does not prevent progressive disease in BALB\/c mice","volume":"73","author":"Iborra","year":"2005","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2010.01.015_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-2478(99)00146-7","article-title":"The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes","volume":"70","author":"Trujillo","year":"2000","journal-title":"Immunol Lett"},{"issue":"5","key":"10.1016\/j.vaccine.2010.01.015_bib22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00436-007-0844-9","article-title":"Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite","volume":"102","author":"Iniesta","year":"2008","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2010.01.015_bib23","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.vaccine.2008.01.042","article-title":"Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis","volume":"26","author":"Carrillo","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2010.01.015_bib24","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.4049\/jimmunol.161.11.6171","article-title":"LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile","volume":"161","author":"Skeiky","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2010.01.015_bib25","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1128\/IAI.66.7.3279-3289.1998","article-title":"Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family","volume":"66","author":"Webb","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.01.015_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0166-6851(97)00115-1","article-title":"Molecular characterization of the heat inducible LmSTI1 protein of Leishmania major","volume":"89","author":"Webb","year":"1997","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2010.01.015_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-2427(02)00315-X","article-title":"A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum","volume":"92","author":"Molano","year":"2003","journal-title":"Vet Immunol Immunopathol"},{"issue":"6\u20137","key":"10.1016\/j.vaccine.2010.01.015_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.0141-9838.2004.00711.x","article-title":"Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG+Q mix protects Balb\/c mice from infection","volume":"26","author":"Parody","year":"2004","journal-title":"Parasite Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2010.01.015_bib29","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect Immun"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2010.01.015_bib30","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL\u00ae adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2010.01.015_bib31","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.01.015_bib32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0092-8674(86)90693-8","article-title":"Speculations on the functions of the major heat shock and glucose-regulated proteins","volume":"46","author":"Pehlam","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2010.01.015_bib33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0092-8674(89)90059-7","article-title":"S. cerevisae encodes an essential protein homologous in sequence and function to mammalian BiP","volume":"57","author":"Normington","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2010.01.015_bib34","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0092-8674(89)90058-5","article-title":"KAR2, a karyogamy gene, is a yeast homolog of mammalian BiP\/grp78","volume":"57","author":"Rose","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2010.01.015_bib35","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1128\/IAI.62.6.2499-2507.1994","article-title":"Molecular cloning and characterization of the 78-kilodalton glucose-regulated protein of Trypanosoma cruzi","volume":"62","author":"Tibbetts","year":"1994","journal-title":"Infect Immunol"},{"issue":"5733","key":"10.1016\/j.vaccine.2010.01.015_bib36","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.1112680","article-title":"The genome of the kinetoplastid parasite, Leishmania major","volume":"309","author":"Ivens","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2010.01.015_bib37","unstructured":"Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, et al. Analysis of genome architecture and content between three Leishmania species causing diverse human disease reveals only a small subset of species-specific genes. (Unpublished data)."},{"issue":"7","key":"10.1016\/j.vaccine.2010.01.015_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ng2053","article-title":"Comparative genomic analysis of three Leishmania species that cause diverse human disease","volume":"39","author":"Peacock","year":"2007","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.vaccine.2010.01.015_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0167-4838(01)00240-0","article-title":"Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani","volume":"1549","author":"Jensen","year":"2001","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.vaccine.2010.01.015_bib40","first-page":"BR117","article-title":"Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin","volume":"8","author":"Mukherjee","year":"2002","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.vaccine.2010.01.015_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1389-0344(01)00101-0","article-title":"Recent developments in adjuvants for vaccines against infectious diseases","volume":"18","author":"O\u2019Hagan","year":"2001","journal-title":"Biomol Eng"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2010.01.015_bib42","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/S0264-410X(01)00058-5","article-title":"Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG","volume":"19","author":"Misra","year":"2001","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2010.01.015_bib43","first-page":"159","article-title":"The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis","volume":"36","author":"Michel","year":"2006","journal-title":"J Egypt Soc Parasitol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.01.015_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1179\/146532806X152890","article-title":"Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major+BCG) in children: an extended phase II study","volume":"26","author":"Khalil","year":"2006","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.vaccine.2010.01.015_bib45","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4049\/jimmunol.148.5.1585","article-title":"In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes","volume":"148","author":"Reddy","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2010.01.015_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(93)90368-H","article-title":"Liposomes as vaccine carriers: incorporation of soluble and particulate antigens in giant vesicles","volume":"166","author":"Antimisiaris","year":"1993","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2010.01.015_bib47","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/IAI.65.6.2371-2377.1997","article-title":"Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes","volume":"65","author":"Afrin","year":"1997","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2010.01.015_bib48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1645\/0022-3395(2000)086[0730:IOPPAL]2.0.CO;2","article-title":"Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes","volume":"86","author":"Afrin","year":"2000","journal-title":"J Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.01.015_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exppara.2006.07.002","article-title":"Leishmania major: immune response in BALB\/c mice immunized with stress-inducible protein 1 encapsulated in liposomes","volume":"115","author":"Badiee","year":"2007","journal-title":"Exp Parasitol"},{"issue":"12","key":"10.1016\/j.vaccine.2010.01.015_bib50","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime\u00ae) and the recombinant Leish-110f\u00ae+MPL-SE\u00ae vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.015_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2010.01.015_bib52","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/meth.1999.0841","article-title":"Vaccine entrapment in liposomes","volume":"19","author":"Gregoriadis","year":"1999","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2010.01.015_bib53","first-page":"119","article-title":"Regulation of Leishmania population within host I. The variable course of Leishmania donovani infection in mice","volume":"30","author":"Bradley","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2010.01.015_bib54","volume":"2","author":"Stuart","year":"1978"},{"key":"10.1016\/j.vaccine.2010.01.015_bib55","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/AAC.45.5.1349-1354.2001","article-title":"Antileishmanial activity of an indole alkaloid from Peschiera australis","volume":"45","author":"Delorenzi","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.vaccine.2010.01.015_bib56","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1128\/IAI.70.12.6697-6706.2002","article-title":"Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB\/c mice","volume":"70","author":"Afrin","year":"2002","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2010.01.015_bib57","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4049\/jimmunol.140.4.1274","article-title":"Effective immunization cutaneous leishmaniasis with defined membrane antigens reconsituted into liposomes","volume":"140","author":"Russell","year":"1988","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.01.015_bib58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0014-4894(90)90127-X","article-title":"Leishmaniamajor: production of recombinant gp63, its antigenicity and immunogenicity in mice","volume":"70","author":"Handman","year":"1990","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2010.01.015_bib59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-3024.1999.00244.x","article-title":"Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection","volume":"21","author":"Rivier","year":"1999","journal-title":"Parasite Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.01.015_bib60","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/(SICI)1521-4141(199902)29:02<522::AID-IMMU522>3.0.CO;2-U","article-title":"Ability of macrophage subsets to transfer resistance to murine leishmaniasis is dependent on IL-12 production","volume":"29","author":"Doherty","year":"1999","journal-title":"Eur J Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2010.01.015_bib61","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1073\/pnas.96.12.6970","article-title":"Immunostimulatory oligonucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-\u03b3 dependent mechanisms","volume":"96","author":"Walker","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2010.01.015_bib62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.vaccine.2008.12.053","article-title":"KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major","volume":"27","author":"Bhaumik","year":"2009","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2010.01.015_bib63","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2007.05.010","article-title":"Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis","volume":"25","author":"Moreno","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.015_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-9292-6-7","article-title":"Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis","volume":"6","author":"Ghalib","year":"2007","journal-title":"Kinetoplastid Biol Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2010.01.015_bib65","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1016\/j.vaccine.2007.05.042","article-title":"Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response","volume":"25","author":"Bhowmick","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2010.01.015_bib66","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/515265","article-title":"Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up","volume":"177","author":"Armijos","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.015_bib67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.parint.2009.07.008","article-title":"Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis","volume":"58","author":"Nagill","year":"2009","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2010.01.015_bib68","first-page":"123","article-title":"Delayed-type hypersensitivity; current theories with an historic perspective","volume":"5","author":"Black","year":"1998","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.vaccine.2010.01.015_bib69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00436-006-0301-1","article-title":"Leishmania major: common antigen responsible for induction of delayed-type hypersensitivity response in guinea pigs","volume":"100","author":"Khabiri","year":"2007","journal-title":"Parasitol Res"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2010.01.015_bib70","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2010.01.015_bib71","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune\u00ae vaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2010.01.015_bib72","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.4049\/jimmunol.166.5.3416","article-title":"General suppression of macrophage gene expression during Leishmania donovani infection","volume":"166","author":"Buates","year":"2001","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.01.015_bib73","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00436-008-1150-x","article-title":"Effect of dose and route of inoculation on the generation of CD4+ Th1\/Th2 type of immune response in murine visceral leishmaniasis","volume":"103","author":"Kaur","year":"2008","journal-title":"Parasitol Res"},{"issue":"5144","key":"10.1016\/j.vaccine.2010.01.015_bib74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.vaccine.2010.01.015_bib75","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2010.01.015_bib76","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.4049\/jimmunol.143.12.4244","article-title":"Experimental visceral leishmaniasis: role of endogenous IFN-\u03b3 in host defense and tissue granulomatous response","volume":"143","author":"Squires","year":"1989","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.01.015_bib77","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/IAI.62.3.1058-1063.1994","article-title":"Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis","volume":"62","author":"Miralles","year":"1994","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2010.01.015_bib78","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/516482","article-title":"Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis","volume":"175","author":"Murray","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.015_bib79","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2249.2003.02096.x","article-title":"Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma","volume":"131","author":"Nylen","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.01.015_bib80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0167-5699(96)80562-7","article-title":"The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example","volume":"17","author":"Kemp","year":"1996","journal-title":"Immunol Today"},{"issue":"1","key":"10.1016\/j.vaccine.2010.01.015_bib81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/107999000312748","article-title":"The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice","volume":"20","author":"Lehmann","year":"2000","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.vaccine.2010.01.015_bib82","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1172\/JCI113969","article-title":"Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated","volume":"83","author":"Carvalho","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2010.01.015_bib83","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0090-1229(90)90038-R","article-title":"Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferongamma production","volume":"57","author":"Zwingenberger","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.01.015_bib84","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1172\/JCI116570","article-title":"Interleukin 10 production correlates with pathology in human Leishmania donovani infections","volume":"92","author":"Ghalib","year":"1993","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.vaccine.2010.01.015_bib85","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/infdis\/173.6.1515","article-title":"Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis","volume":"173","author":"Bacellar","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.015_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-2478(98)00132-1","article-title":"T-cell response in human leishmaniasis","volume":"65","author":"Kharazmi","year":"1999","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2010.01.015_bib87","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.171.1.115","article-title":"Cure of murine leishmaniasis with anti interleukin 4 monoclonal antibody","volume":"171","author":"Sadick","year":"1990","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.vaccine.2010.01.015_bib88","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1084\/jem.194.10.1497","article-title":"The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure","volume":"194","author":"Belkaid","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2010.01.015_bib89","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/1521-4141(200111)31:11<3175::AID-IMMU3175>3.0.CO;2-L","article-title":"Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB\/c mice","volume":"31","author":"Uzonna","year":"2001","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2010.01.015_bib90","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/IAI.70.11.6284-6293.2002","article-title":"Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy","volume":"70","author":"Murray","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2010.01.015_bib91","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1383-5769(02)00039-9","article-title":"IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection","volume":"51","author":"Viana da Costa","year":"2002","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2010.01.015_bib92","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.0.CO;2-T","article-title":"IL-10 mediates susceptibility to Leishmania donovani infection","volume":"31","author":"Murphy","year":"2001","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.01.015_bib93","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI112209","article-title":"Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis","volume":"76","author":"Carvalho","year":"1985","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.vaccine.2010.01.015_bib94","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.4049\/jimmunol.154.9.4623","article-title":"IL-12 enhances Th1-type responses in human Leishmania donovani infections","volume":"154","author":"Ghalib","year":"1995","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.01.015_bib95","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2249.1997.tb08318.x","article-title":"Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis","volume":"110","author":"Rafati","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.01.015_bib96","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1128\/IAI.73.6.3787-3789.2005","article-title":"Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses","volume":"73","author":"da Costa Pinheiro","year":"2005","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2010.01.015_bib97","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2249.2004.02702.x","article-title":"Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response","volume":"139","author":"Farajnia","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.01.015_bib98","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-3083.1998.00370.x","article-title":"Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11","volume":"48","author":"Jensen","year":"1998","journal-title":"Scand J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2010.01.015_bib99","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.4049\/jimmunol.146.11.3697","article-title":"Universal vaccine carrier: liposomes that provide T dependent help to weak antigens","volume":"146","author":"Garcon","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2010.01.015_bib100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0264-410X(92)90395-Z","article-title":"Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response","volume":"10","author":"Abraham","year":"1992","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T01:11:46Z","timestamp":1711156306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":100,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0264410X10000460"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.01.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}